Editorial: Hepatosplenic T-cell lymphoma and TNF-α inhibitors

Expert Review of Hematology

Volumn 2, Issue 6, 2009, Pages 611-614

  Pozadzides, Jenny Vu ^a   Pro, Barbara ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CLINICAL FEATURE; DISEASE COURSE; EDITORIAL; HUMAN; PRIORITY JOURNAL; T CELL LYMPHOMA; ADULT; DRUG ANTAGONISM; IMMUNOSUPPRESSIVE TREATMENT; LIVER TUMOR; MALE; MORTALITY; PATHOPHYSIOLOGY; SPLEEN TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOSUPPRESSION; LIVER NEOPLASMS; LYMPHOMA, T-CELL; MALE; SPLENIC NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77953410121     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.09.62     Document Type: Editorial

References (46)

1. Farcet, JP, Gaulard P, Marolleau JP et al. Hepatosplenic T-cell lymphoma: sinusal/ sinusoidal localization of malignant cells expressing the T-cell receptor gd. Blood 75(11), 2213-2219 (1990).
2. Kadin ME, Kamoun M, Lamberg J et al. Erythrophagocytic T g lymphoma: a clinicopathologic entity resembling malignant histiocytosis. N. Engl. J. Med. 304(11), 648-653 (1981).
3. Gaulard P, Bourquelot P, Kanavaros P et al. Expression of the a/b and g/d T-cell receptors in 57 cases of peripheral T-cell lymphomas. Identification of a subset of g/d T-cell lymphomas. Am. J. Pathol. 137(3), 617-628 (1990).
4. Thayu M, Markowitz JE, Mamula P, Russo PA, Muinos WI, Baldassano RN. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J. Pediatr. Gastroenterol. Nutr. 40(2), 220-222 (2005).
5. Belhadj K, Reyes F, Farcet JP et al. Hepatosplenic gd T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 102(13), 4261-4269 (2003).
6. Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm. Bowel Dis. 13(8), 1024-1030(2007).
7. Weidmann E. Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 14(6), 991-997 (2000).
8. Hanson MN, Morrison VA, Peterson PA et al. Posttransplant T-cell lymphoproliferative disorders - an aggressive, late complication of solid-organ transplantation. Blood 88(9), 3626-3633 (1996).
9. Roelandt PR, Maertens J, Vandenberghe P et al. Hepatosplenic gd T-cell lymphoma after liver transplantation: report of the first 2 cases and review of the literature. Liver Transpl. 15(7), 686-692 (2009).
10. Falchook GS, Vega F, Dang NH et al. Hepatosplenic g-d T-cell lymphoma: clinicopathological features and treatment. Ann. Oncol. 20(6), 1080-1085 (2000).
11. Dincol G, Nalcaci M, Yavuz AS et al. Case of hepatosplenic gd T-cell lymphoma presenting with severe hypersplenism. Am. J. Hematol. 60(4), 313-314 (1999).
12. Jaffe ES, Ralfkiaer E. Hepatosplenic T-cell lymphoma. In: World Health Organization Classification of Tumours: Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissue. Jaffe ES, Harris NL, Stein H et al. (Eds). IARC Press, Lyon, France 210 (2001).
13. Weidmann E, Hinz T, Klein S et al. Cytotoxic hepatosplenic gd T-cell lymphoma following acute myeloid leukemia bearing two distinct g chains of the T-cell receptor. Biologic and clinical features. Haematologica 85(10), 1024-1031 (2000).
14. Vega F, Medeiros LJ, Bueso-Ramos E et al. Hepatosplenic g/d T-cell lymphoma in bone marrow. A sinusoidal neoplasm with blastic cytologic features. Am. J. Clin. Pathol. 116(3), 410-419 (2001).
15. De Wolf-Peeters C, Achten R. gd T-cell lymphomas: a homogenous entity? Histopathology 36, 294-305 (2000).
16. Przybylski GK, Wu H, Macon WR et al. Hepatosplenic and subcutaneous panniculitis-like g/d T cell lymphomas are derived from different Vd subsets of g/d T lymphocytes. J. Mol. Diagn. 2(1), 11-19 (2000).
17. Macon WR, Levy NB, Kurtin PJ et al. Hepatosplenic ab T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gd T-cell lymphomas. Am. J. Surg. Pathol. 25(3), 285-296 (2001).
18. Krenacs L, Smyth MJ, Bagdi E et al. The serine protease granzyme M is preferentially expressed in NK-cell, g d T-cell, and intestinal T-cell lymphomas: evidence of origin from lymphocytes involved in innate immunity. Blood 101(9), 3590-3593 (2003).
19. Jonveaux P, Daniel MT, Martel V, Maarek O, Berger R. Isochromosome 7q and trisomy 8 are consistent primary, non-random chromosomal abnormalities associated with hepatosplenic T g/d lymphoma. Leukemia 10(9), 1453-1455 (1996).
20. Ghobrial IM, Habermann TM, Maurer MJ et al. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J. Clin. Oncol. 23(30), 7574-7582 (2005).
21. Sallah S, Smith SV, Lony LC, Woodard P, Schmitz JL, Folds JD. g/d T-cell hepatosplenic lymphoma: review of the literature, diagnosis by flow cytometry and concomitant autoimmune hemolytic anemia. Ann. Hematol. 74(3), 139-142 (1997).
22. Rossbach HC, Chamizo W, Dumont DP, Barbosa JL, Sutcliffe MJ. Hepatosplenic g/d T-cell lymphoma with isochromosome 7q, translocation t(7;21), and tetrasomy 8 in a 9-year-old girl. J. Pediatr. Hematol. Oncol. 24(2), 154-157 (2002).
23. Khan WA, Yu L, Eisenbrey AB et al. Hepatosplenic g/d T-cell lymphoma in immunocompromised patients. Report of two cases and review of literature. Am. J. Clin. Pathol. 116(1), 41-50 (2001).
24. Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 57(12), 1639-1641 (2008).
25. Francois A, Lesesve JF, Stamatoullas A et al. Hepatosplenic g/d T-cell lymphoma: a report of two cases in immunocompromised patients, associated with isochromosome 7q. Am. J. Surg. Pathol. 21(7), 781-790 (1997).
26. Kraus MD, Crawford DF, Kaleem Z, Shenoy S, MacArthur CA, Longtine JA. T g/d hepatosplenic lymphoma in a heart transplant patient after an Epstein-Barr virus positive lymphoproliferative disorder: a case report. Cancer 82(5), 983-992 (1998).
27. Roncella S, Cutrona G, Truini M et al. Late Epstein-Barr virus infection of a hepatosplenic gd T-cell lymphoma arising in a kidney transplant recipient. Haematologica 85(3), 256-262 (2000).
28. Steurer M, Stauder R, Grunewald K et al. Hepatosplenic gd-T-cell lymphoma with leukemic course after renal transplantation. Hum. Pathol. 33(2), 253-258 (2002).
29. Hassan R, Franco SA, Stefanoff CG et al. Hepatosplenic gd T-cell lymphoma following seven malaria infections. Pathol. Int. 56(11), 668-673 (2006).
30. Navarro JT, Ribera JM, Mate JL et al. Hepatosplenic T-gd lymphoma in a patient with Crohn's disease treated with azathioprine. Leuk. Lymphoma 44(3), 531-533 (2003).
31. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 44(2), 265-267 (2007).
32. Wu H, Wasik MA, Przybylski G et al. Hepatosplenic g-d T-cell lymphoma as a late-onset posttransplant lymphoproliferative disorder in renal transplant recipients. Am. J. Clin. Pathol. 113(4), 487-496 (2000).
33. Ohshima K, Haraoka S, Harada N et al. Hepatosplenic gd T-cell lymphoma: relation to Epstein-Barr virus and activated cytotoxic molecules. Histopathology 36(2), 127-135 (2000).
34. Beigel F, Jurgens M, Tillack C et al. Hepatosplenic T-cell lymphoma in a patient with Crohn's disease. Nat. Rev. Gastroenterol. Hepatol. 6(7), 433-436 (2009).
35. Ardizzone S, Bianchi Porro G. Inflammatory bowel disease: new insights into pathogenesis and treatment. J. Intern. Med. 252(6), 475-496 (2002).
36. Cornillie F, Shealy D, D'Haens G et al. Infliximab induces potent antiinflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment. Pharmacol. Ther. 15(4), 463-473 (2001).
37. Veres G, Baldassano RN, Mamula P. Infliximab therapy in children and adolescents with inflammatory bowel disease. Drugs 67(12), 1703-1723 (2007).
38. Veres G, Baldassano RN, Mamula P. Infliximab therapy for pediatric Crohn's disease. Expert Opin. Biol. Ther. 7(12), 1869-1880 (2007).
39. Louis E, Ribbens C, Godon A et al. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin. Exp. Immunol. 120(2), 241-246 (2000).
40. Mackey AC, Green L, Leptak C, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J. Pediatr. Gastroenterol. Nutr. 48(3), 386-388 (2009).
41. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359(9317), 1541-1549 (2002).
42. Beaugerie L, Carrat F, Bouvier A et al. Excess risk of lymphoproliferative disorders (LPD) in inflammatory bowel diseases (IBD), interim results of the CESAME cohort. Gastroenterology 134(Suppl. 1), A116-A117 (2008).
43. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54(8), 1121-1125 (2005).
44. Sokol H, Beaugerie L. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut 58(10), 1427-1436 (2009).
45. Colombel JF, Loftus EV Jr, Tremaine WJ et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126(1), 19-31 (2004).
46. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: metaanalysis of placebo-controlled trials. Clin. Gastroenterol. Hepatol. 6(6), 644-653 (2008).